available at www.sciencedirect.com

SciVerse ScienceDirect

www.elsevier.com/locate/molonc

Editorial

Julio E. Celis

It is now six years since FEBS started *Molecular Oncology* with the aim of providing the broad cancer community with a forum for the publication of new discoveries, approaches, as well as state-of-the-art technical developments, in basic, clinical and discovery-driven translational cancer research.

During the last years we have seen a striking raise in the number of manuscripts submitted to the Journal, a near-exponential growth in the number of article downloads, as well as a steady increase in its impact factor which now stands at 6.701. These encouraging developments in our journal metrics are in great part due to the engagement and commitment of our Editorial Board members, who have supported the Journal by providing much needed advice about current trends in cancer research, submitting articles, reviewing manuscripts, writing reviews as well as suggesting and editing Thematic Issues.

In line with our current journal policy, seven estimated colleagues will rotate off the Editorial Board this year and I would like to take this opportunity to express our gratitude to Boris Bastian, Peter Boyle, Ronald Herberman, David Kerr, Edith Oláh, Ian Stratford, and John Yates on behalf of FEBS and Elsevier for their engagement and commitment to the Journal. It has been a privilege and a great pleasure working with them.

To keep pace with current developments in cancer research we have recently appointed seven new Editorial Board members that include Geneviève Almouzni, Carlos Caldas, Manuel Hidalgo, Marco Pierotti, Josep Tabernero, Paul Workman and Laurence Zitvogel. Brief biographies are included in this issue as well as in the journal Website www.journals.elsevier.com/molecular-oncology/.

In the expectation that the increase in the impact factor will, most likely, lead to a significant increase in the number

of submission, we have decided to increase the number of issues published per year from six to eight starting in 2014. The Journal will continue to publish original articles, invited reviews, and news & views in science policy issues. We will also continue publishing Thematic Issues as these highlight hot cancer topics, help to structure the field, and have an educational component. Three Thematic Issues are currently under preparation, the first focuses on Cancer Immunology (edited by Lisa Coussens, Karolina Palucka and Laurence Zitvogel), the second on Critical Issues on Biomarkers Discovery and Validation (edited by Alan Spatz and Leon van Kempen), and the third on Personalized Cancer Medicine, a follow up to the successful 2012 Issue edited by John Mendelsohn, Ulrik Ringborg and Richard Schilsky.

Finally, I would like to thank our Managing Editor José Moreira for his constant support and dedication, in particular in the organisation of the Thematic Issues as well as Dorte Holst Pedersen who runs the office in a most effective way. Needless to say, however, that at the end of the day the success of the journal depends very much on your continuous support. We are looking forward to receiving your contributions.

Julio E. Celis, Editor-in-Chief
Danish Cancer Society Research Center, Strandboulevarden 49,
2100 Copenhagen, Denmark
E-mail address: jec@cancer.dk

1574-7891/\$ – see front matter
© 2013 Published by Elsevier B.V. on behalf of Federation of
European Biochemical Societies.
<http://dx.doi.org/10.1016/j.molonc.2013.07.003>